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Background: Adults with serious mental illness have a mortality rate two to three times higher than the overall US
population, much of which is due to somatic conditions, especially cardiovascular disease. Given the
disproportionately high prevalence of cardiovascular risk factors in the population with SMI, screening for these
conditions is an important first step for timely diagnosis and appropriate treatment. This comprehensive literature
review summarizes screening rates for cardiovascular risk factors in the population with serious mental illness.
Methods: Relevant articles published between 2000 and 2013 were identified using the EMBASE, PsychInfo,
PubMed, SCOPUS and Web of Science databases. We reviewed 10 studies measuring screening rates for obesity,
diabetes, dyslipidemia, and hypertension in the population with serious mental illness. Two reviewers
independently extracted information on screening rates, study population, and study setting.
Results: Rates of screening varied considerably by time period, study population, and data source for all medical
conditions. For example, rates of lipid testing for antipsychotic users ranged from 6% to 85%. For some conditions,
rates of screening were consistently high. For example, screening rates for hypertension ranged from 79% - 88%.
Conclusions: There is considerable variation in screening of cardiovascular risk factors in the population with
serious mental illness, with significant need for improvement in some study populations and settings.
Implementation of standard screening protocols triggered by diagnosis of serious mental illness or antipsychotic
use may be promising avenues for ensuring timely diagnosis and treatment of cardiovascular risk factors in this
population.Background
Persons with serious mental illnesses (SMI) such as
schizophrenia and bipolar disorder have a mortality rate
two to three times higher than the overall United States
(US) population [1,2]. Much of this premature mortality
is due to comorbid somatic conditions, particularly car-
diovascular disease [3-6]. Those with SMI experience a
high burden of cardiovascular risk factors, including
obesity, diabetes, dyslipidemia, and hypertension [7,8].
Elevated rates of cardiovascular risk factors in this group
are driven by low rates of physical activity, [9] poor diet,
[10] high rates of smoking, [11] and the obesogenic ef-
fects of commonly prescribed antipsychotic medications* Correspondence: gdaumit@jhmi.edu
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unless otherwise stated.[12], which often cause weight gain and alter glucose
metabolism.
Given the disproportionately high prevalence of cardio-
vascular risk factors in the population with SMI, screening
for these conditions is an important first step for timely
diagnosis and appropriate treatment. The United States
Preventive Services Task Force (USPSTF), a federal panel
of experts in prevention and evidence-based medicine,
makes recommendations about systematic screening in
primary care for the overall US population. For example,
all Americans with sustained blood pressure greater than
135/80 mmHg are recommended to be screened for dia-
betes mellitus [13]. These recommendations are based on
strong bodies of research evidence demonstrating that the
preventive service leads to improved health outcomes,
which is often the result of diagnosis and effective treat-
ment following screening [13].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Psychiatric Association, American Association of Clinical
Edocrinologists, and North American Association for the
Study of Obesity (hereafter referred to as the “ADA/APA
consensus panel”) [14] released guidelines for screening
and monitoring of somatic conditions among anti-
psychotic users, many of whom have SMI. The ADA/APA
consensus panel guidelines recommend more frequent
screening for and monitoring of cardiovascular risk factors
among antipsychotic users than the USPSTF guidelines
recommend for the overall US population. Unlike the
USPTF guidelines, which are based on robust bodies of re-
search evidence demonstrating a link between guideline-
concordant screening and improved health outcomes, the
ADA/APA guidelines are based on physician consensus.
Although research suggests that the population of
adults with SMI experiences a disproportionately high
burden of treatable cardiovascular risk factors [15,16]
and that systematic screening and treatment may im-
prove health outcomes, [17,18] to our knowledge no
comprehensive review of the literature exists regarding
rates of screening for cardiovascular risk factors in the
population with SMI. To fill this gap, we reviewed the
peer-reviewed literature published between January 2000
and December 2013 to summarize measures of screen-
ing for cardiovascular risk factors in the population with
SMI. We abstracted measures related to screening for
cardiovascular risk factors in various study samples of
persons with SMI.
Methods
Development of our review followed a modified
PRISMA (Preferred Reporting Items for Systematic Re-
views and Meta-Analyses) framework, an evidence-based
set of items for reporting reviews. The goal of our review
was to summarize descriptive measures of screening
rates for cardiovascular risk factors in the adult popula-
tion with SMI. We used a structured review protocol
(Additional file 1) to abstract measures of screening for
cardiovascular risk factors in study populations with
SMI. A key limitation to our modified approach was our
inability to systematically assess the quality of the in-
cluded studies. Because we excluded randomized clinical
trials and other intervention studies, we did assess the
risk of bias for individual studies as is typically done in
systematic reviews of clinical trials. These bias assess-
ments focus on indicators of internal validity, which are
not relevant for purely descriptive studies. We did in-
clude observational studies that assessed screening rates
at multiple time points, for example before and after the
release of relevant clinical guidelines. For these studies,
we abstracted and presented screening time period-
specific screening rates, e.g. rates for both 2002–2003
and 2005–2007.In our final review, we abstracted measures of screening
for five cardiovascular risk factors and one risk behavior
shown by prior research to be highly prevalent among the
population with SMI: [16,19-21] (1) overweight and obes-
ity; (2) diabetes mellitus; (3) dyslipidemia; (4) hyperten-
sion; and (5) tobacco use. We also searched for studies
measuring rates of screening for tobacco use among
persons with SMI. We searched EMBASE, PsychInfo,
PubMed, SCOPUS and Web of Science for studies pub-
lished from January 2000 through December 2013 that
measured screening rates for the conditions listed
above in the population with SMI. Full search strategies
are included in Additional file 2. For the purposes of
this review, we defined SMI as schizophrenia or bipolar
disorder. Studies that included persons with other diagno-
ses, such as major depression or post-traumatic stress dis-
order (PTSD) were included if the study also included
participants with schizophrenia or bipolar disorder. Studies
comprised entirely of persons with major depression,
PTSD, or other conditions were excluded.
Studies were included in our comprehensive review
if (1) they were published between January 2000 and
December 2013; (2) they were published in English; (3)
they included participants aged 18 years or older; (4)
they measured rate of screening for cardiovascular risk
in a study population with SMI; (5) the study sample in-
cluded 50 or more participants; (6) the study took place
in the US; (7) the study population included persons
with schizophrenia or bipolar disorder; and (8) the study
was observational. As the goal of this review was to as-
sess rates of screening for cardiovascular risk factors in
usual-care scenarios for persons with SMI, randomized
clinical trials and other intervention studies designed to
improve screening rates were excluded from this manu-
script and included in a separate review of intervention
studies by the same authors.
Two reviewers abstracted measures of screening for
cardiovascular risk factors from the articles (for example,
glucose testing among persons with schizophrenia to
screen for diabetes mellitus). The reviewers abstracted
data about the study design and population, including
year(s) the data was collected, number of study partici-
pants, the study population’s SMI diagnoses and anti-
psychotic use, and study setting characteristics including
type of setting (e.g. inpatient, outpatient, non-clinical
community), geographic location (e.g. national, state),
and other population characteristics (e.g. veterans or
Medicaid beneficiaries). A copy of the abstraction tool is
included in Additional file 1.
Using data abstracted from the studies included in our
review, we compiled all available measures and created
tables including information on the measurement indi-
cator, data source, study population, year of data, and
measures of screening in the population with SMI,
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screening rate (e.g. annual screening, screening in the
30 days after antipsychotic medication initiation, etc.).
We then compared rates of screening for cardiovascular
risk factors in the studies reviewed to national quality of
care guidelines. When national estimates were available,
we compared screening rates in the population with
SMI to screening rates in the overall US population. As
no human subjects were involved in this research, in-
formed consent for participation was not obtained and
institutional review board review of the study was not
required.
Results
Our search yielded a total of 136 studies (Figure 1). One
hundred twenty-six studies were excluded for failure to
meet inclusion criteria; in this category, most studies
were excluded for not having an outcome measure ofFigure 1 PRISMA flow diagram, included studies.interest. A total of 10 studies were included in our re-
view. Included studies measured screening rates for
overweight and obesity, diabetes mellitus, dyslipidemia,
and hypertension. While we also searched for studies
measuring rates of screening for tobacco use in the
population with SMI, no studies measuring this outcome
that met our inclusion criteria were identified.
Demographic characteristics of the study populations
reviewed
The demographic characteristics of the study popula-
tions included in our review are shown in Table 1. Popu-
lations varied by sex, race, and SMI diagnoses. Overall,
most studies included adults between the ages of 18 and
65. Six of the 10 included studies had populations com-
prised 100% of persons with schizophrenia or bipolar
disorder. Six study populations were made up entirely of
antipsychotic medication users, and the remaining four
Table 1 Study population characteristics




Kilbourne, 2011 [22] 18-65 55 9% female 24% black, 100% Schizophrenia 100%
76% other
Morrato, 2008 [25] All ages Not reported 50% female 58% white, 100% Schizophrenia1 100%
42% other
Moeller, 2011 [26] 18-64 44 49% female 83% white, 100% Schizophrenia 100%
17% other




Kaplowitz, 2006 [30] 20+ 67 4% female Not reported 51.0% Mood disorders,
including bipolar disorder
Not reported
Weissman, 2006 [31] 18-65 50 6% female Not reported 100% Schizophrenia 100%
Barnett, 2010 [32] 21-63 45 59% female 43% white, Not reported 100%
14% black,
43% other
Kilbourne, 2008 [34] 18+ 67 3% female 8% black, 100% Schizophrenia, bipolar
disorder, or other psychosis2
Not reported
92% other
Folsom, 2002 [35] 45+ 51 47% female 70% white, 100% Schizophrenia3 Not reported
15% black,
15% other





1The full study population also included individuals with other or no mental health diagnoses, but all screening measures abstracted for this review were assessed
in the study population with schizophrenia only.
2The full study population also included individuals with depression and individuals with no psychiatric diagnoses, but all screening measures abstracted for this
review were assessed in the study population with schizophrenia, bipolar disorder, or other psychoses only.
3The full study population also included individuals with depression, but all screening measures abstracted for this review were assessed in the study population
with schizophrenia only.
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using antipsychotics.
Overweight and obesity (Panel 1)
The USPSTF recommends screening all adults for obesity
[13]. For antipsychotic users with SMI, the ADA/APA
consensus panel recommends screening for overweight
and obesity at time of antipsychotic initiation, four, eight,
and 12 weeks after initiation of a new antipsychotic medi-
cation, and four times per year thereafter [14].
In our review, we found one study that measured over-
weight and obesity screening in the population with
SMI. One hundred percent of this population was taking
antipsychotics. The screening and monitoring rate for
overweight and obesity was relatively high (76%)
(Table 2) [22]. This study consisted of a 2007 veteran
population. Participants were considered to have been
screened for obesity if their BMI was measured twice in
2007. In comparison to the population with SMI, 50% ofvisits to office-based physicians in the US had the height
and weight measurements necessary to screen for over-
weight and obesity using Body Mass Index (BMI) in
2005–2006, [23] and in 2010, 71% of office-based phys-
ician visits included weight assessments (Table 3) [24].
Diabetes mellitus (Panel 2)
The USPSTF recommends screening for diabetes mellitus
in asymptomatic adults with sustained blood pressure
(either treated or untreated) greater than 135/80 mmHg
[13]. For antipsychotic users with SMI, the ADA/APA
consensus panel recommends screening for diabetes
mellitus at time of antipsychotic initiation, three
months after initiation of a new antipsychotic medica-
tion, and annually thereafter [14].
In our review, we found six studies that measured dia-
betes mellitus screening in the population with SMI,
totaling 12 measures. One hundred percent of the study
population was taking antipsychotics for nine of the
Table 2 Measures of screening for cardiovascular risk factors in persons with serious mental illness, 2000-2013
Study population Main finding in words References
Panel 1: Screening for Overweight and Obesity
Body Mass Index
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Outpatient Veterans participating in the
National Psychosis Registry, | Screening year(s): 2007 | Time window for ascertaining
screening rate: Bi-annual | Data source: Administrative claims
76% of patients had Body Mass Index (BMI) assessed in 2007 Kilbourne, 2011 [22]
Panel 2: Screening for Diabetes Mellitus
Glucose screening
N: 55436 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and Outpatient Medicaid
beneficiaries from California, Oregon, Tennessee and Utah | Screening year(s): 1998–2003 |
Time window for ascertaining screening rate: 14 days prior-28 days after second
generation antipsychotic initiation | Data source: Administrative claims
18% of those without schizophrenia and 23% of those with schizophrenia
had a glucose test during 1998-2003
Morrato, 2008 [25]
Compared to those without schizophrenia, those with schizophrenia had 1.5
times greater odds of having a glucose test during 1998–2003 (p < .05)
N: 18876 | % of study sample with schizophrenia or bipolar disorder: 3.4%
schizophrenia and 49.3% mood disorders, including bipolar disorder | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient commercial health
insurance beneficiaries | Screening year(s): 2001–2006 | Time window for ascertaining
screening rate: 30 days prior-30 days after second generation antipsychotic initiation | Data
source: Administrative claims
The mean glucose testing rate for antipsychotic-treated patients was 23%
during 2001-2006
Morrato, 2009 [27]
N: 2204 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid
beneficiaries | Screening year(s): 2003 | Time window for ascertaining screening rate:
Annual | Data source: Administrative claims
23% of patients had a glucose test during 2002-2003 Moeller, 2011 [26]
29% of patients with dyslipidemia had a glucose test during 2002-2003
N: 1646| % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid
beneficiaries| Screening year(s): 2005-2007| Time window for ascertaining screening
rate: Annual | Data source: Administrative claims
75% of patients had a glucose test during 2005-2007
65% of patients with dyslipidemia had a glucose test during 2005-2007
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported |
Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California
Medicaid recipients | Screening year(s): 2004-2005| Time window for ascertaining
screening rate: Six months prior to-6 months after second generation antipsychotic
initiation| Data source: Administrative claims
24% of patients had a glucose test in the six months prior to antipsychotic
initiation during 2004-2005
Barnett, 2010 [32]
28% of patients had a glucose test in the six months after antipsychotic
initiation during 2004-2005
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Outpatient Veterans participating in the
National Psychosis Registry | Screening year(s): 2007 | Time window for ascertaining
screening rate: Bi-annual | Data source: Administrative claims
60% of patients had at least two glucose tests in 2007 Kilbourne, 2011 [22]
Glucose and Lipids Screening
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported |
Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California
Medicaid recipients | Screening year(s): 2004–2005 | Time window for ascertaining
screening rate: Six months prior-6 months after second generation antipsychotic initiation|
Data source: Administrative claims
23% of patients had both a glucose test and a lipid test in the six months
prior to antipsychotic initiation during 2004-2005
Barnett, 2010 [32]
27% of patients had both a glucose test and a lipid test in the six months
after antipsychotic initiation during 2004-2005











Table 2 Measures of screening for cardiovascular risk factors in persons with serious mental illness, 2000-2013 (Continued)
Any Lipid Screening
N: 200 | % of study sample with schizophrenia or bipolar disorder: 75% | Percent
antipsychotic users: Not reported | Study population: Outpatients from psychiatric care
centers in Baltimore, MD | Screening year(s): 2000 | Time window for ascertaining
screening rate: Annual| Data source: Interview data
In 2000, 51% of patients reported having had their cholesterol checked in the
past year
Dickerson 2003 [38]
N: 55436 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and Outpatient Medicaid
beneficiaries from California, Oregon, Tennessee and Utah | Screening year(s): 1998–2003 |
Time window for ascertaining screening rate: 14 days prior-28 days after second
generation antipsychotic initiation | Data source: Administrative claims
6% of those without schizophrenia and 9% of those with schizophrenia had
a lipid test during 1998-2003
Morrato, 2008 [25]
Compared to those without schizophrenia, those with schizophrenia had 1.4
times greater odds of having a lipid test during 1998–2003 (p < .05)
N: 94 | % of study sample with schizophrenia or bipolar disorder: 100% Percent
antipsychotic users: Not reported | Study population: Outpatient homeless shelter clinic
users | Screening year(s): 1999–2000 | Time window for ascertaining screening rate:
Annual | Data source: Medical chart review
55% of those with schizophrenia had a lipid test during 1999-2000 Folsom, 2002 [35]
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans |
Screening year(s): 1999–2003 | Time window for ascertaining screening rate: Four years
| Data source: Administrative claims
85% of patients had at least one lipid test during 1999-2003 Weissman, 2006 [31]
27% of patients had only one lipid test during 1999-2003
N: 64,490 | % of study sample with schizophrenia or bipolar disorder: 51% mood
disorders, including bipolar disorder| Percent antipsychotic users: Not reported | Study
population: Outpatient Veterans from New England Health Care System | Screening year
(s): 2000–2001 | Time window for ascertaining screening rate: Annual | Data source:
Administrative claims
85% of patients with mental illness had a lipid test, compared to 78% of
patients without mental illness in 2001
Kaplowitz, 2006 [30]
Compared to those without SMI, those with SMI had 2.73 times greater odds
of having a lipid test in 2001 (p < .05)
N: 18876 | % of study sample with schizophrenia or bipolar disorder: 3.4%
schizophrenia, 49.3% mood disorders, including bipolar disorder| Percent antipsychotic
users: 100% | Study population: Inpatient and outpatient commercial health insurance
beneficiaries | Screening year(s): 2001–2006 | Time window for ascertaining screening
rate: 30 days prior-30 days after second generation antipsychotic initiation | Data source:
Administrative claims
The mean lipid testing rate for antipsychotic-treated patients was 8% during
2001-2006
Morrato, 2009 [27]
N: 2204| % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Kansas Medicaid
beneficiaries | Screening year(s): 2003| Time window for ascertaining screening rate:
Annual | Data source: Administrative claims
10% of patients had a lipid test during 2002-2003 Moeller, 2011 [26]
N: 1646| Diagnoses: Schizophrenia | Percent antipsychotic users: 100% | Study
population: Inpatient and outpatient Kansas Medicaid beneficiaries | Screening year(s):
2005–2007 | Time window for ascertaining screening rate: Annual | Data source:
Administrative claims
53% of patients had a lipid test during 2005-2007
N: 6601 | % of study sample with schizophrenia or bipolar disorder: Not reported|
Percent antipsychotic users: 100% | Study population: Inpatient and outpatient California
Medicaid recipients | Screening year(s): 2004–2005 | Time window for ascertaining
screening rate: Six months prior-6 months after second generation antipsychotic initiation |
Data source: Administrative claims
39% of patients had a lipid test in the six months prior to antipsychotic
initiation during 2004-2005
Barnett, 2010 [32]
43% of patients had a lipid test in the six months after antipsychotic
initiation during 2004-2005
N: 46,430 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: Not reported | Study population: Inpatient or outpatient veterans
with hyperlipidemia participating in National Psychosis Registry | Screening year(s): 2005 |
90% of those with SMI, 94% of those with depression, and 94% of those












Table 2 Measures of screening for cardiovascular risk factors in persons with serious mental illness, 2000-2013 (Continued)
Time window for ascertaining screening rate: Annual | Data source: Medical chart
review
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% |Percent
antipsychotic users: 100% | Study population: Outpatient Veterans participating in the
National Psychosis Registry| Screening year(s): 2007 | Time window for ascertaining
screening rate: Annual | Data source: Administrative claims
37% of patients had a lipid test in 2007 Kilbourne, 2011 [22]
Low Density Lipoprotein (LDL) Screening
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans |
Screening year(s): 1999–2003 | Time window for ascertaining screening rate: four years|
Data source: Administrative claims
74% of patients had at least one LDL test during 1999-2003 Weissman, 2006 [31]
28% of patients had only one LDL test during 1999-2003
Triglyceride Screening
N: 408 | % of study sample with schizophrenia or bipolar disorder: 100% | Percent
antipsychotic users: 100% | Study population: Inpatient and outpatient Veterans |
Screening year(s): 1999–2003 | Time window for ascertaining screening rate: four years
| Data source: Administrative claims
85% of patients had at least one triglycerides test during 1999-2003 Weissman, 2006 [31]
27% of patients had only one triglycerides test during 1999-2003
Panel 4: Screening for Hypertension
Any Blood Pressure Assessment
N: 200 | % of study sample with schizophrenia or bipolar disorder: 75%| Percent
antipsychotic users: Not reported | Study population: Outpatients from psychiatric care
centers in Baltimore, MD | Screening year(s): 2000 | Time window for ascertaining
screening rate: Annual| Data source: Interview data
In 2000, 88% of patients reported having had their blood pressure checked in
the past year
Dickerson 2003 [38]
N: 40600 | % of study sample with schizophrenia or bipolar disorder: 100% |Percent
antipsychotic users: 100% | Study population: Outpatient Veterans participating in the
National Psychosis Registry | Screening year(s): 2007 | Time window for ascertaining
screening rate: Annual | Data source: Administrative claims











Table 3 Adherence to national quality guidelines in persons with serious mental illness and the overall population
USPSTF recommendation [13] Studies (N) Measures
abstracted(N)
Population with SMI Overall population
Range in screening rates National estimates of percent screened
Panel 1: Screening for Overweight and Obesity
Screening all adults for obesity 1 1 Screening rate: 76% [22] Screening year: 2007 National estimates: 50% [23] - 71% [24] (2010)
Panel 2: Screening for Diabetes
Screening for type 2 diabetes in asymptomatic adults with
sustained blood pressure greater than 135/80 mmHg
5 10 Lowest screening rate: 23% [25] Screening year(s):
1998-2003
National estimates: 94% [29] (2005–2007)
Highest screening rate: 75% [26] Screening year(s):
2005-2007
Panel 3: Screening for Dyslipidemia
Screening for lipid disorders (Men: aged 35+; or 20-35+
if at increased risk for coronary heart disease; Women:
aged 20+ if at increased risk for coronary heart disease)
10 17 Lowest screening rate: 6% [25] Screening year(s):
1998-2003
National estimates: 68% [36] (1999–2006) - 79%
[24] (2011)
Highest screening rate: 90% [34] Screening year(s): 2005
Panel 4: Screening for Hypertension
Screening for high blood pressure in adults 2 2 Lowest screening rate: 79% [54] Screening year(s): 2007 National estimates: 59% [24] - 64% [40] (2010)
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chotics for one measure, and 0% of the population was
taking antipsychotics for two measures. Glucose screen-
ing ranged from 18%-75%, and glucose and lipids
screening ranged from 23%-27%. Glucose screening rates
tended to increase over time, with 18%-29% of patients
receiving screening between 1998–2003, [25,26] and
60%-75% receiving screening from 2006–2007 [22,26].
Low screening rates occurred in both commercial health
insurance and Medicaid beneficiaries; testing rates below
30% among antipsychotic users were found in popula-
tions of commercial health insurance beneficiaries from
2001-2006 [27] and Medicaid beneficiaries with SMI
from 2000–2003 [25,26]. In contrast, another study
found that 60% of veterans with SMI using antipsy-
chotics had at least two glucose tests in 2007 (Table 2)
[28]. The time windows for ascertaining diabetes mellitus
screening rates ranged from rates calculated in the 14 days
prior to and 28 days after initiation of second-generation
antipsychotics to annual rates. Screening rates tended to
be lower when shorter time windows were employed. In
comparison to the study population with SMI, from
2005–2007, 94% of patients from a Midwest academic
physician group who met USPSTF guidelines for diabetes
screening received a glucose test (Table 3) [29].
Dyslipidemia (Panel 3)
The USPSTF recommends lipid screening for men aged
35 and older, men aged 20–35 if they are at increased
risk of coronary heart disease, and women aged 20 and
older if they are at increased risk of coronary heart dis-
ease [13]. For antipsychotic users with SMI, the ADA/
APA consensus panel recommends screening for
dyslipidemia at time of antipsychotic initiation, three
months after antipsychotic initiation, and every five
years thereafter [14].
In our review, we found 10 studies that measured dys-
lipidemia screening in the population with SMI, totaling
12 measures. One hundred percent of the population
was taking antipsychotics for 13 of the measures, 22% of
the population were taking antipsychotics for one of the
measures, and antipsychotic use was not reported for
three of the measures. Estimated rates of lipid testing
among antipsychotic users with SMI ranged from 8% of
beneficiaries in four commercial health plans during
2001-2006 [27] to 85% of veterans during 2000–2001
[30]. In the majority of studies, lipid screening rates
among antipsychotic users were less than 50% (Table 2)
[25-28,31-35]. One study measured low density lipopro-
tein (LDL) screening and triglyceride screening, finding
that 74% of veterans had at least one LDL test and 85%
had at least one triglyceride test during 1999–2003 [31].
The time windows for ascertaining dyslipidemia screen-
ing rates varied, ranging from the period spanning14 days prior-28 days after initiation of second-generation
antipsychotic medication to four years. In comparison to
the population with SMI, 68%-79% of visits to office-based
physicians included testing for lipids or cholesterol among
high-risk groups (Table 3) [36,37].
Hypertension (Panel 4)
The USPSTF recommends screening for hypertension in
adults aged 18 and older. For antipsychotic users with
SMI, [13] the ADA/APA consensus panel recommends
screening for hypertension at time of antipsychotic initi-
ation, three months after antipsychotic initiation, and
annually thereafter [14].
In our review, we found two studies that measured
hypertension screening in the population with SMI, total-
ing two measures. One hundred percent of the population
was taking antipsychotics for one measure, and anti-
psychotic use was not reported for the other measure.
Screening and monitoring rates for hypertension were
generally high. Both measures showed rates of 79% or
higher for any blood pressure measurement (Table 2)
[22,38]. The time windows used to ascertain hypertension
screening rates were one year [22] and four years, [38] re-
spectively. In comparison to the study populations with
SMI, in 2010, 59%-64% of US adults’ visits to the doctor
included a blood pressure check (Table 3) [39,40].
In summary, we found that rates of cardiovascular
screening varied considerably in the studies reviewed.
Only one study measured overweight and obesity, and it
found that 76% of patients with schizophrenia has BMI
assessed in a given year. Rates of screening for diabetes
mellitus ranged from 18% [25] to 75% [26]. Screening
for dyslipidemia among adults with SMI ranged from 8%
[25] to 85%, [31] Finally, screening for hypertension
ranged from 79% [22] to 88% [38]. Estimates of screen-
ing rates for obesity and hypertension in the population
with SMI were comparable – or higher, in the case of
hypertension – to estimates of national screening rates
for these conditions. For diabetes and dyslipidemia, the
highest screening rates abstracted from studies of the
SMI population were comparable to national rates, but
the lowest rates were significantly lower. For example,
national estimates of dyslipidemia screening range from
68% to 79%, and the lowest dyslipidemia screening rate
in the population with SMI abstracted from the studies
we reviewed was 6%. While we provide these general
population rates for comparison, it is important to
understand differences in time period, patient mix and
settings across these studies in interpreting screening
in SMI and non-SMI populations. Moreover, expert
guidelines for persons with SMI taking antipsychotics
recommend more frequent screening for cardiovascular
risk factors than guidelines for the overall US popula-
tion [14].
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We found that rates of screening for cardiovascular risk
factors in the population with SMI varied considerably
in the studies reviewed. Much of this variation is likely
attributable to health system differences, such as
whether or not a given system has a standard protocol
for screening for cardiovascular risk factors among anti-
psychotic users. Implementation of standard screening
protocols is feasible and an effective tool for improving
rates of screening. For example, six recent studies
showed significant improvements in rates of screening
for obesity in patients with SMI following implementa-
tion of standard screening protocols [41-46].
While health system differences may account for some
of the variation in screening rates across the studies we
reviewed, other important factors may help to explain
this variability. Screening rates may change over time
due to secular trends in medical practice. Variation in
screening rates may also be due to differences in measure-
ment technique (e.g. administrative claims data versus
chart review) and the time window used to ascertain the
screening rate. To be included in our review, study popu-
lations had to include – but were not limited to – persons
with schizophrenia and bipolar disorder. Differences in
diagnostic distribution within study populations could also
influence variation in screening rates; however, the ma-
jority of study populations reviewed were comprised
primarily of persons with schizophrenia and bipolar
disorder using antipsychotic medications and no dis-
cernable patterns in screening rates by diagnostic com-
position of study sample were observed in our results.
Consistent with prior work, the results of our review
suggest that rates measured over short time windows, for
example in the 30 days following initiation of anti-
psychotic medication, tend to be lower than rates mea-
sured over longer periods [47]. In addition, rates are likely
influenced by the frequency of patients’ encounters with
the healthcare system. Patients who are frequent users of
medical care services are more likely to be screened [48].
In addition, prior work has shown that individuals with
more pre-existing risk factors for a condition are more
likely to be screened for that condition [48]. Screening
rates may be higher among those with pre-existing risk
factors because providers prioritize screening among
patients at heightened risk. This group may also be sicker
and therefore more likely to use health services – increas-
ing their chances of being screened due to increased con-
tact with the healthcare system [48].
Variation in rates of screening for cardiovascular risk
factors in the population with SMI is likely caused by
multiple factors, including providers’ experience treating
persons with SMI, [49] co-located versus geographically
separate medical and mental health services, [18] and
degree of continuity and coordination among medicalcare providers [50,51]. Consistent with studies evaluating
quality of care conducted in the overall US population,
[52,53] screening rates for cardiovascular risk factors
among those with SMI tended to be high in the Veterans
Health Administration (VHA) [22,30,31,54-56]. This is
likely due at least partly to the VHA’s ability, as a national
system, to use electronic patient data to trigger standard
screening protocols for cardiovascular risk factors [57].
Ongoing initiatives to implement electronic health records
in other health systems may provide an important tool to
improve quality of medical care for persons with SMI [58].
The ongoing implementation of the Affordable Care
Act presents a multitude of opportunities to improve
screening for and treatment of cardiovascular risk fac-
tors among persons with SMI through initiatives such as
Accountable Care Organizations (ACOs), Medicaid
Health Homes, and state demonstration projects to inte-
grate care for persons with SMI who are dually eligible
for Medicare and Medicaid [50]. All three initiatives
focus on coordinating care for populations with complex
health needs, such as adults with SMI, to ensure that
those with positive screenings receive appropriate
follow-up treatment. Additionally, these initiatives rely
heavily on health information technology, which can
facilitate clinical decision support interventions and im-
prove care coordination and patient outcomes [59-61].
Rigorous evaluation of these efforts is critical in order to
understand how these new initiatives can best address
the high burden of medical conditions and improve
long-term health outcomes in the population with SMI.
Health homes, Accountable Care Organizations, and
other integrated care and quality improvement initiatives
use performance metrics to measure health system per-
formance and, increasingly, determine rates of reim-
bursement and shared savings for physicians [62].
Quality measurement can be an important tool to drive
quality improvement in the healthcare system. In
response to the increased risk of metabolic syndrome
associated with use of antipsychotics, the National
Committee for Quality Assurance (NCQA), a private
organization dedicated to improving the quality of
health care in the US, released new quality measures in
2014 relating to diabetes and cardiovascular disease
screening and monitoring for adults with SMI who are
using antipsychotic medications [63]. More specifically,
the NCQA defines three new measures: 1) diabetes
screening for people with schizophrenia or bipolar
disorder who are using antipsychotic medications; 2)
diabetes monitoring for people with diabetes and
schizophrenia; and 3) cardiovascular monitoring for
people with cardiovascular disease and schizophrenia.
Measurement of diabetes and cardiovascular disease
screening and monitoring for adults with SMI will help
to elucidate opportunities for improvement.
Baller et al. BMC Psychiatry  (2015) 15:55 Page 11 of 13To our knowledge, this is the first study to provide a
comprehensive review and compilation of screening rates
for cardiovascular risk factors in the US population with
SMI. The results of our review have several implications.
First, the variation in screening rates suggests that re-
searchers and practitioners interested in improving
screening for cardiovascular conditions in this vulnerable
population need to take into account unique healthcare
setting, measurement, and population characteristics
when designing and evaluating screening programs. Sec-
ond, our results suggest that rates of screening for cardio-
vascular risk factors are very low in some study
populations of persons with SMI, suggesting a need for
improved implementation of screening in some settings.
Third and perhaps most critically, our review identified
considerable variation in the measurement and reporting
of screening for cardiovascular risk factors in the popula-
tion with SMI, making it difficult to compare screening
rates across studies and with national rates. Given growing
national interest in improving care and reducing costs for
the population with SMI, there may be opportunities
moving forward to standardize measurement and
reporting of cardiovascular risk factor screening rates
in this population. For example, 95% of persons with
schizophrenia are insured by government programs:
Medicaid and the Veteran’s Health Administration [64].
These insurers are already required to report multiple
administrative-claims based measures of care quality to
the federal government. Requiring these programs to
report standardized measures of cardiovascular risk
screening – for example the new NCQA measures de-
scribed above – for beneficiaries with SMI would provide
a critical tool for quality improvement and allow re-
searchers and policy makers to monitor national screening
rates over time.
These results should be interpreted in the context of
several limitations. First, the screening measures ab-
stracted from studies were not always directly comparable
with one another or with national measures. The timing
of measures varied, with some studies measuring a screen-
ing indicator within a one year period and others measur-
ing over a longer period of time. Additionally, the patient
characteristics of the included studies varied, which could
have implications for receipt of cardiovascular screening
tests as patient demographic characteristics have associ-
ated with receipt of preventive services in prior research
[65], it is possible that our search strategy missed relevant
articles, although to minimize this risk we searched the
reference list of included articles. In addition, because our
study does not include interventions or randomized trials,
we did not systematically assess the internal validity of the
included studies, as is standard in systematic reviews of
clinical trials. Screening rates extracted from the studies in
our review may be subject to measurement error,particularly those that estimate screening using adminis-
trative claims data. Prior research has shown that claims
data underestimates services for some chronic conditions,
such as obesity. To aid in interpretation of results, we
presented information about data source, measurement
specification, and the time window in which the screening
rate was measured. Other potential sources of bias to our
results include selective reporting within studies and pub-
lication bias, but we were unable to identify the extent of
these threats to validity based on the content of the studies
reviewed.
Conclusion
In this comprehensive literature review, rates of screening
for cardiovascular risk factors in the population with SMI
varied considerably by time period and study population.
There is substantial need for improvement in providing
routine screening and appropriate follow-up care for
cardiovascular risk factors among some subpopulations
with SMI. Research suggests that implementation of
standard screening protocols triggered by SMI diagnosis
or antipsychotic use are promising avenues for early iden-
tification of cardiovascular risk factors in the population
with SMI [66]. Future research should consider how best
to connect screening to the other processes of care – in-
cluding diagnosis, treatment, and monitoring – necessary
in order to improve health outcomes for people with SMI.
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